Company intelligence / Profile preview
Clarus Therapeutics
Northbrook, Illinois, United Statessec.gov ↗
- Ownership
- Private
- Development stage
- NDA
01
Overview
Clarus Therapeutics developed JATENZO, an FDA-approved oral testosterone replacement therapy for men with hypogonadism. The product is a proprietary softgel capsule containing testosterone undecanoate formulated for intestinal lymphatic system absorption.
- Therapeutic areas
- Women's HealthEndocrinologyRare DiseasesNephrology
- Modalities
- Small molecule drugsChemical drugs
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Verity Pharmaceuticals, Inc.St. Louis UniversityUniversity of Miami
Beyond the preview
Go deeper on Clarus Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Clarus Therapeutics.